Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131


Aging and HIV infection: focus on cardiovascular disease risk.

Aberg JA.

Top Antivir Med. 2020 Jan;27(4):102-105.


Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination.

Fitch KV, Kileel EM, Looby SE, Zanni MV, Sanchez LR, Fichtenbaum CJ, Overton ET, Malvestutto C, Aberg JA, Klingman KL, Alston-Smith B, Lavelle J, Rancourt A, Badal-Faesen S, Cardoso SW, Avihingsanon A, Patil S, Sponseller CA, Melbourne K, Ribaudo HJ, Cooper-Arnold K, Desvigne-Nickens P, Hoffmann U, Douglas PS, Grinspoon SK; REPRIEVE Investigators.

HIV Res Clin Pract. 2020 Feb;21(1):11-23. doi: 10.1080/25787489.2020.1733794. Epub 2020 Mar 11.


Oral Cytokine Levels Are More Linked to Levels of Plasma and Oral HIV-1 RNA Than to CD4+ T-Cell Counts in People With HIV.

Rocco JM, York Z, Shen C, Shiboski C, Cyriaque-Webster J, McLaughlin J, Borowski L, Chen H, Aberg JA, Dittmer DP, Ghannoum M, Rinaldo CR, Macatangay B.

Open Forum Infect Dis. 2020 Feb 13;7(3):ofaa047. doi: 10.1093/ofid/ofaa047. eCollection 2020 Mar.


The Science and Value of Diversity: Closing the Gaps in Our Understanding of Inclusion and Diversity.

Swartz TH, Palermo AS, Masur SK, Aberg JA.

J Infect Dis. 2019 Aug 20;220(Supplement_2):S33-S41. doi: 10.1093/infdis/jiz174.


Combined estimation of disease progression and retention on antiretroviral therapy among treated individuals with HIV in the USA: a modelling study.

Wang L, Krebs E, Min JE, Mathews WC, Nijhawan A, Somboonwit C, Aberg JA, Moore RD, Gebo KA, Nosyk B; HIV Research Network.

Lancet HIV. 2019 Aug;6(8):e531-e539. doi: 10.1016/S2352-3018(19)30148-1. Epub 2019 Jul 11.


Targeting thrombogenicity and inflammation in chronic HIV infection.

O'Brien MP, Zafar MU, Rodriguez JC, Okoroafor I, Heyison A, Cavanagh K, Rodriguez-Caprio G, Weinberg A, Escolar G, Aberg JA, Badimon JJ.

Sci Adv. 2019 Jun 12;5(6):eaav5463. doi: 10.1126/sciadv.aav5463. eCollection 2019 Jun.


Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE).

Grinspoon SK, Fitch KV, Overton ET, Fichtenbaum CJ, Zanni MV, Aberg JA, Malvestutto C, Lu MT, Currier JS, Sponseller CA, Waclawiw M, Alston-Smith B, Cooper-Arnold K, Klingman KL, Desvigne-Nickens P, Hoffmann U, Ribaudo HJ, Douglas PS; REPRIEVE Investigators.

Am Heart J. 2019 Jun;212:23-35. doi: 10.1016/j.ahj.2018.12.016. Epub 2019 Mar 4.


Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Hoffmann U, Lu MT, Olalere D, Adami EC, Osborne MT, Ivanov A, Aluru JS, Lee S, Arifovic N, Overton ET, Fichtenbaum CJ, Aberg JA, Alston-Smith B, Klingman KL, Waclawiw M, Burdo TH, Williams KC, Zanni MV, Desvigne-Nickens P, Cooper-Arnold K, Fitch KV, Ribaudo H, Douglas PS, Grinspoon SK; REPRIEVE Investigators.

Am Heart J. 2019 Jun;212:1-12. doi: 10.1016/j.ahj.2019.02.011. Epub 2019 Mar 4.


Human Immunodeficiency Virus (HIV) Viral Suppression After Transition From Having No Healthcare Coverage and Relying on Ryan White HIV/AIDS Program Support to Medicaid or Private Health Insurance.

Raifman J, Althoff K, Rebeiro PF, Mathews WC, Cheever LW, Hauck H, Aberg JA, Gebo KA, Moore R, Berry SA; HIV Research Network.

Clin Infect Dis. 2019 Jul 18;69(3):538-541. doi: 10.1093/cid/ciy1088.


Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial.

Toribio M, Fitch KV, Stone L, Zanni MV, Lo J, de Filippi C, Sponseller CA, Lee H, Grundberg I, Thompson MA, Aberg JA, Grinspoon SK.

EBioMedicine. 2018 Sep;35:58-66. doi: 10.1016/j.ebiom.2018.08.039. Epub 2018 Aug 31.


Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.

Cespedes MS, Kang M, Kojic EM, Umbleja T, Godfrey C, Webster-Cyriaque JY, Masih R, Firnhaber C, Grinsztejn B, Saah A, Cu-Uvin S, Aberg JA.

Papillomavirus Res. 2018 Dec;6:15-21. doi: 10.1016/j.pvr.2018.08.002. Epub 2018 Aug 16.


Soluble levels of receptor for advanced glycation endproducts and dysfunctional high-density lipoprotein in persons infected with human immunodeficiency virus: ACTG NWCS332.

Kelesidis T, Kendall MA, Danoff A, Aberg JA, Currier JS, Schmidt AM.

Medicine (Baltimore). 2018 Jun;97(22):e10955. doi: 10.1097/MD.0000000000010955.


Human Immunodeficiency Virus Medicine Association Pain Management Guidelines Needed to Curb Opioid Epidemic.

Gandhi V, Nurutdinova D, Milunka Kojic E, Aberg JA.

Clin Infect Dis. 2018 Mar 19;66(7):1152-1153. doi: 10.1093/cid/cix932. No abstract available.


Diversity in the US Infectious Diseases Workforce: Challenges for Women and Underrepresented Minorities.

Aberg JA, Blankson J, Marrazzo J, Adimora AA.

J Infect Dis. 2017 Sep 15;216(suppl_5):S606-S610. doi: 10.1093/infdis/jix332.


Assessing Antiretroviral Use During Gaps in HIV Primary Care Using Multisite Medicaid Claims and Clinical Data.

Monroe AK, Fleishman JA, Voss CC, Keruly JC, Nijhawan AE, Agwu AL, Aberg JA, Rutstein RM, Moore RD, Gebo KA; HIV Research Network.

J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):82-89. doi: 10.1097/QAI.0000000000001469.


Gonorrhea and Chlamydia Case Detection Increased When Testing Increased in a Multisite US HIV Cohort, 2004-2014.

Raifman JR, Gebo KA, Mathews WC, Korthuis PT, Ghanem KG, Aberg JA, Moore RD, Nijhawan AE, Monroe AK, Berry SA; HIV Research Network.

J Acquir Immune Defic Syndr. 2017 Dec 1;76(4):409-416. doi: 10.1097/QAI.0000000000001514.


Oral shedding of herpesviruses in HIV-infected patients with varying degrees of immune status.

Dittmer DP, Tamburro K, Chen H, Lee A, Sanders MK, Wade TA, Napravnik S, Webster-Cyriaque J, Ghannoum M, Shiboski CH, Aberg JA.

AIDS. 2017 Sep 24;31(15):2077-2084. doi: 10.1097/QAD.0000000000001589.


Aging with HIV in the ART era.

Kaplan-Lewis E, Aberg JA, Lee M.

Semin Diagn Pathol. 2017 Jul;34(4):384-397. doi: 10.1053/j.semdp.2017.04.002. Epub 2017 Apr 6. Review.


A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy.

O'Brien MP, Hunt PW, Kitch DW, Klingman K, Stein JH, Funderburg NT, Berger JS, Tebas P, Clagett B, Moisi D, Utay NS, Aweeka F, Aberg JA.

Open Forum Infect Dis. 2017 Jan 19;4(1):ofw278. doi: 10.1093/ofid/ofw278. eCollection 2017 Winter.


Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.

Aberg JA, Sponseller CA, Ward DJ, Kryzhanovski VA, Campbell SE, Thompson MA.

Lancet HIV. 2017 Jul;4(7):e284-e294. doi: 10.1016/S2352-3018(17)30075-9. Epub 2017 Apr 13. Erratum in: Lancet HIV. 2017 Jul;4(7):e283.


Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).

Nixon DE, Bosch RJ, Chan ES, Funderburg NT, Hodder S, Lake JE, Lederman MM, Klingman KL, Aberg JA; AIDS Clinical Trials Group Study A5275 Team.

J Clin Lipidol. 2017 Jan - Feb;11(1):61-69. doi: 10.1016/j.jacl.2016.09.017. Epub 2016 Oct 5.


JCL roundtable: Managing lipid disorders in patients with HIV.

Brown WV, Aberg JA, Aspry KE, Longenecker CT, Myerson M.

J Clin Lipidol. 2017 Jan - Feb;11(1):4-11. doi: 10.1016/j.jacl.2016.12.003. Epub 2016 Dec 14. Review.


Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.

Toribio M, Fitch KV, Sanchez L, Burdo TH, Williams KC, Sponseller CA, McCurdy Pate M, Aberg JA, Zanni MV, Grinspoon SK.

AIDS. 2017 Mar 27;31(6):797-806. doi: 10.1097/QAD.0000000000001427.


Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort.

Agwu AL, Fleishman JA, Mahiane G, Nonyane BA, Althoff KN, Yehia BR, Berry SA, Rutstein R, Nijhawan A, Mathews C, Aberg JA, Keruly JC, Moore RD, Gebo KA; HIV Research Network.

PLoS One. 2017 Feb 9;12(2):e0171125. doi: 10.1371/journal.pone.0171125. eCollection 2017.


High Rates of Anal High-Grade Squamous Intraepithelial Lesions in HIV-Infected Women Who Do Not Meet Screening Guidelines.

Gaisa M, Ita-Nagy F, Sigel K, Arens Y, Hennessy MA, Rodriguez-Caprio G, Mullen M, Aberg JA, Cespedes M.

Clin Infect Dis. 2017 Feb 1;64(3):289-294. doi: 10.1093/cid/ciw729. Epub 2016 Nov 9.


Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy.

Kaplan-Lewis E, Aberg JA, Lee M.

Curr HIV/AIDS Rep. 2016 Oct;13(5):297-308. doi: 10.1007/s11904-016-0331-y. Review.


Soluble Levels of Receptor for Advanced Glycation Endproducts (RAGE) and Progression of Atherosclerosis in Individuals Infected with Human Immunodeficiency Virus: ACTG NWCS 332.

Danoff A, Kendall MA, Currier JS, Kelesidis T, Schmidt AM, Aberg JA.

Inflammation. 2016 Aug;39(4):1354-62. doi: 10.1007/s10753-016-0367-6.


Prediabetes and diabetes among HIV-infected adults in Cameroon.

Rhee JY, Bahtila TD, Palmer D, Tih PM, Aberg JA, LeRoith D, Jao J.

Diabetes Metab Res Rev. 2016 Sep;32(6):544-9. doi: 10.1002/dmrr.2792. Epub 2016 Apr 6.


National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2.

Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA; NLA Expert Panel.

J Clin Lipidol. 2015 Nov-Dec;9(6 Suppl):S1-122.e1. doi: 10.1016/j.jacl.2015.09.002. Epub 2015 Sep 18. Erratum in: J Clin Lipidol. 2016 Jan-Feb;10(1):211. Underberg, James A [added].


High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group.

Shiboski CH, Chen H, Secours R, Lee A, Webster-Cyriaque J, Ghannoum M, Evans S, Bernard D, Reznik D, Dittmer DP, Hosey L, Sévère P, Aberg JA; Oral HIV/AIDS Research Alliance, Subcommittee of the AIDS Clinical Trial Group.

PLoS One. 2015 Jul 6;10(7):e0131001. doi: 10.1371/journal.pone.0131001. eCollection 2015.


Management of lipid disorders in patients living with HIV.

Myerson M, Malvestutto C, Aberg JA.

J Clin Pharmacol. 2015 Sep;55(9):957-74. doi: 10.1002/jcph.473. Epub 2015 Jun 23. Review.


Design aspects of a case-control clinical investigation of the effect of HIV on oral and gastrointestinal soluble innate factors and microbes.

Phelan JA, Abrams WR, Norman RG, Li Y, Laverty M, Corby PM, Nembhard J, Neri D, Barber CA, Aberg JA, Fisch GS, Poles MA, Malamud D.

PLoS One. 2014 Nov 19;9(11):e112901. doi: 10.1371/journal.pone.0112901. eCollection 2014.


Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir.

Malvestutto CD, Ma Q, Morse GD, Underberg JA, Aberg JA.

J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):390-6. doi: 10.1097/QAI.0000000000000333.


Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Günthard HF, Aberg JA, Eron JJ, Hoy JF, Telenti A, Benson CA, Burger DM, Cahn P, Gallant JE, Glesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA; International Antiviral Society-USA Panel.

JAMA. 2014 Jul 23-30;312(4):410-25. doi: 10.1001/jama.2014.8722.


Differentiation of IL-17-producing effector and regulatory human T cells from lineage-committed naive precursors.

Mercer F, Khaitan A, Kozhaya L, Aberg JA, Unutmaz D.

J Immunol. 2014 Aug 1;193(3):1047-54. doi: 10.4049/jimmunol.1302936. Epub 2014 Jun 23.


Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.

Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, Saah A, Aberg JA, Cu-Uvin S.

Clin Infect Dis. 2014 Jul 1;59(1):127-35. doi: 10.1093/cid/ciu238. Epub 2014 Apr 9.


Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.

Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, Aberg JA.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):172-80. doi: 10.1097/QAI.0000000000000149.


Reply to Monroe and Brown.

Danoff A, Horberg M, Aberg JA.

Clin Infect Dis. 2014 Jun;58(11):1640-1. doi: 10.1093/cid/ciu131. Epub 2014 Mar 5. No abstract available.


Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA; Infectious Diseases Society of America.

Clin Infect Dis. 2014 Jan;58(1):1-10. doi: 10.1093/cid/cit757.


Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268.

Cespedes MS, Kerns SL, Holzman RS, McLaren PJ, Ostrer H, Aberg JA.

HIV Clin Trials. 2013 Nov-Dec;14(6):292-302. doi: 10.1310/hct1406-292.


Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA; Infectious Diseases Society of America.

Clin Infect Dis. 2014 Jan;58(1):e1-34. doi: 10.1093/cid/cit665. Epub 2013 Nov 13.


Care for transgender persons.

Danoff A, Daskalakis D, Aberg JA.

JAMA. 2013 May 22;309(20):2092-3. doi: 10.1001/jama.2013.4662. No abstract available.


Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.

O'Brien M, Montenont E, Hu L, Nardi MA, Valdes V, Merolla M, Gettenberg G, Cavanagh K, Aberg JA, Bhardwaj N, Berger JS.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):280-8. doi: 10.1097/QAI.0b013e31828a292c.


Clash of the microbes: let's bring back the good guys.

Wolff MJ, Poles MA, Aberg JA.

J Clin Invest. 2013 Feb;123(2):544-5. doi: 10.1172/JCI66736. Epub 2013 Jan 16.


Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.

Cespedes MS, Castor D, Ford SL, Lee D, Lou Y, Pakes GE, Aberg JA.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):550-4. doi: 10.1097/QAI.0b013e318285d918.


Aging, inflammation, and HIV infection.

Aberg JA.

Top Antivir Med. 2012 Aug-Sep;20(3):101-5. Review.


Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.

Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Günthard HF, Hammer SM, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA.

JAMA. 2012 Jul 25;308(4):387-402. doi: 10.1001/jama.2012.7961.


Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City.

Doshi S, Chen TF, Zapata J, Holzman RS, Zapata LC, Aberg JA, Sivapalasingam S.

Int J Infect Dis. 2012 Jul;16(7):e518-21. doi: 10.1016/j.ijid.2012.03.002. Epub 2012 Apr 26.


Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.

Aberg JA, Tebas P, Overton ET, Gupta SK, Sax PE, Landay A, Falcon R, Ryan R, De La Rosa G.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1184-95. Epub 2012 Apr 2.


Glycated Hemoglobin A(1c) as screening for diabetes mellitus in HIV-infected individuals.

Eckhardt BJ, Holzman RS, Kwan CK, Baghdadi J, Aberg JA.

AIDS Patient Care STDS. 2012 Apr;26(4):197-201. doi: 10.1089/apc.2011.0379. Epub 2012 Feb 10.

Supplemental Content

Loading ...
Support Center